Artículos de revistas
Erbb-2 Expression And Hormone Receptor Status In Areas Of Transition From In Situ To Invasive Ductal Breast Carcinoma [expressão Da Proteína Erbb-2 E Dos Receptores De Hormônios Na Transição Das Regiões In Situ Para Invasora De Tumores Da Mama]
Registro en:
Revista Brasileira De Ginecologia E Obstetricia. , v. 31, n. 9, p. 461 - 467, 2009.
1007203
2-s2.0-70350646844
Autor
Peres R.M.R.
Derchain S.F.M.
Heinrich J.K.R.
Serra K.P.
Pinto G.A.
Soares F.A.
Sarian L.O.Z.
Institución
Resumen
PURPOSE: to evaluate the expression of erbB-2 and of the estrogen and progesterone (ER/P) hormonal receptors in the transition regions between the in situ and the invasive fractions of ductal breast neoplasia (ISDC and IDC, respectively). METHODS: Eighty-five cases of breast neoplasia, containing contiguous ISDC and IDC areas, were selected. Histological specimens from the ISDC and the IDC areas were obtained through the tissue microarray (TMA) technique. The erbB-2 and the ER/PR expressions were evaluated through conventional immunohistochemistry. The McNemar's test was used for the comparative analysis of the expressions of erbB-2 protein and the ER/PR in the in situ and invasive regions of the tumors. The confidence intervals were set to 5% (p=0.05). Intraclass correlation coefficients (ICC) were calculated to assess the cross-tabulation agreement of the erbB-2 and the ER/PR expression in the ISDC and the IDC areas. RESULTS: the erbB-2 expression has not differed between the ISDC and the IDC areas (p=0.38). Comparing the two areas in each case, there was agreement in the expression of erbB-2 (ICC=0.64), PR (ICC=0.71) and ER (ICC=0.64). Restricting the analysis to tumors with the in situ component harboring necrosis (comedo), the ICC for erbB-2 was 0.4, compared to 0.6 for the whole sample. In this select group, the ICC for PR/ER did not differ substantially from those obtained with the complete dataset: as for the ER, ICC=0.7 (versus 0.7 for the entire sample) and for PR, ICC=0.7 (versus 0.6 for the entire sample). CONCLUSIONS: our findings suggest that the erbB-2 and the ER/PR expressions do not differ in the contiguous in situ and invasive components of breast ductal tumors. 31 9 461 467 Schnitt, S.J., The transition from ductal carcinoma in situ to invasive breast cancer: The other side of the coin (2009) Breast Cancer Res., 11 (1), p. 101 Wiechmann, L., Kuerer, H.M., The molecular journey from ductal carcinoma in situ to invasive breast cancer (2008) Cancer, 112 (10), pp. 2130-42 Skinner, K.A., Silverstein, M.J., The management of ductal carcinoma in situ of the breast (2001) Endocr Relat Cancer, 8 (1), pp. 33-45 (2008) Drogas de alvo molecular na oncologia e hematologia [Internet], , http://www.nibsemabs.com.br/bases.asp?id=1, Nibs & Mabs, citado 2008 Set 6, Disponível em Latta, E.K., Tjan, S., Parkes, R.K., O'Malley, F.P., The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast (2002) Mod Pathol., 15 (12), pp. 1318-25 Hussein, M.R., Abd-Elwahed, S.R., Abdulwahed, A.R., Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast (2008) Cell Biol Int., 32 (6), pp. 698-707 Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Estrogen receptors: How do they signal and what are their targets (2007) Physiol Rev., 87 (3), pp. 905-31 Provenzano, E., Hopper, J.L., Giles, G.G., Marr, G., Venter, D.J., Armes, J.E., Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast (2003) Eur J Cancer, 39 (5), pp. 622-30 Wärnberg, F., Nordgren, H., Bergkvist, L., Holmberg, L., Tumour markers in breast carcinoma correlate with grade rather than with invasiveness (2001) Br J Cancer, 85 (6), pp. 869-74 Gusterson, B.A., Machin, L.G., Gullick, W.J., Gibbs, N.M., Powles, T.J., Price, P., Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer (1988) Int J Cancer, 42 (6), pp. 842-5 Park, K., Han, S., Kim, H.J., Kim, J., Shin, E., HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry (2006) Histopathology, 48 (6), pp. 702-7 Sauter, G., Lee, J., Bartlett, J.M., Slamon, D.J., Press, M.F., Guidelines for human epidermal growth factor receptor 2 testing: Biologic and methodologic considerations (2009) J Clin Oncol., 27 (8), pp. 1323-33 http://cran.r-project.org/doc/manuals/refman.pdf, The R Development Core Team. R: a language and environment for statistical computing: reference index [Internet]. Vienna: R Foundation for Statistical Computing 2009 [cited 2009 Apr 20]. Available fromMoasser, M.M., The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis (2007) Oncogene, 26 (45), pp. 6469-87 Castro, N.P., Osorio, C.A., Torres, C., Bastos, E.P., Mourão-Neto, M., Soares, F.A., Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma (2008) Breast Cancer Res., 10 (5), pp. R87 Soomro, S., Shousha, S., Taylor, P., Shepard, H.M., Feldmann, M., C-erbB-2 expression in different histological types of invasive breast carcinoma (1991) J Clin Pathol, 44 (3), pp. 211-4 Sommerville, J.E., Clarke, L.A., Biggart, J.D., c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma (1992) J Clin Pathol., 45 (1), pp. 16-20 Iglehart, J.D., Kerns, B.J., Huper, G., Marks, J.R., Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer (1995) Breast Cancer Res Treat, 34 (3), pp. 253-63 Man, Y.G., Zhang, Y., Shen, T., Zeng, X., Tauler, J., Mulshine, J.L., cDNA expression profiling reveals elevated gene expression in cell clusters overlying focally disrupted myoepithelial cell layers: Implications for breast tumor invasion (2005) Breast Cancer Res Treat, 89 (2), pp. 199-208 Man, Y.G., Shen, T., Weisz, J., Berg, P.E., Schwartz, A.M., Mulshine, J.L., A subset of in situ breast tumor cell clusters lacks expression of proliferation and progression related markers but shows signs of stromal and vascular invasion (2005) Cancer Detect Prev, 29 (4), pp. 323-31 Bose, S., Lesser, M.L., Norton, L., Rosen, P.P., Immunophenotype of intraductal carcinoma (1996) Arch Pathol Lab Med., 120 (1), pp. 81-5 Moreno, A., Lloveras, B., Figueras, A., Escobedo, A., Ramon, J.M., Sierra, A., Ductal carcinoma in situ of the breast: Correlation between histologic classifications and biologic markers (1997) Mod Pathol., 10 (11), pp. 1088-92 Mack, L., Kerkvliet, N., Doig, G., O'Malley, F.P., Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, c-erb B2, bcl-2, and ki-67 (1997) Hum Pathol, 28 (8), pp. 974-9 Meijnen, P., Peterse, J.L., Antonini, N., Rutgers, E.J., van de Vijver, M.J., Immunohistochemical categorisation of ductal carcinoma in situ of the breast (2008) Br J Cancer, 98 (1), pp. 137-42 Kononen, J., Bubendorf, L., Kallioniemi, A., Bärlund, M., Schraml, P., Leighton, S., Tissue microarrays for high-throughput molecular profiling of tumor specimens (1998) Nat Med, 4 (7), pp. 844-7